GSM5359412
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311153 | — | — | 0.843 |
| 2 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.840 |
| 3 | TCGA-XX-A899-01A-11R-A36F-07 | — | A | 0.834 |
| 4 | R60 | — | — | 0.830 |
| 5 | C3L-02170 | — | cohortMD2 | 0.830 |
| 6 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.821 |
| 7 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.821 |
| 8 | BS_FQX1PRAJ | Neurofibroma | — | 0.811 |
| 9 | BS_GDHH6T5A | Neurofibroma | — | 0.807 |
| 10 | BS_Z28VKGNS | Neurofibroma | — | 0.805 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.480 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| HYPOXIA | 0.190 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |